2 deals
Vaccination biotech Vaxxas raises $49 million Series D, cuts C-suite amid broader layoffs
Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.
Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily